Baxter's most recent trend suggests a bullish bias. One trading opportunity on Baxter is a Bull Put Spread using a strike $59.00 short put and a strike $54.00 long put offers a potential 5.49% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $59.00 by expiration. The full premium credit of $0.26 would be kept by the premium seller. The risk of $4.74 would be incurred if the stock dropped below the $54.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Baxter is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Baxter is bullish.
The RSI indicator is at 76.95 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Baxter
Baxter Announces U.S. FDA Approval and Commercial Launch of Ready-to-Use Clindamycin Injection in Saline
Wed, 07 Jun 2017 15:00:00 +0000
Baxter International Inc. , a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations .
Baxter Presents Data on Telehealth’s Role in Improving Peritoneal Dialysis Patient Care at ERA-EDTA 2017
Mon, 05 Jun 2017 20:05:00 +0000
Baxter International Inc. , a global innovator in renal care, presented new data demonstrating the abilities of its SHARESOURCE remote patient management technology to improve peritoneal dialysis patient care and increase dialysis clinic efficiencies.
New Data Demonstrates High Performance of HDx Enabled by THERANOVA, Baxter’s Novel Hemodialysis Therapy
Mon, 05 Jun 2017 12:00:00 +0000
Baxter International Inc. , a global innovator in renal care, highlighted new data on its novel HDx therapy enabled by the THERANOVA dialyzer at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association , June 3-6.
Daniel Loeb's Favorite Idea Spurs May Outperformance
Fri, 02 Jun 2017 22:41:02 +0000
High-conviction top position is more than twice size of next biggest
Baxter International, Inc. : BAX-US: Dividend Analysis : June 02nd, 2017 (record date) : By the numbers : June 1, 2017
Thu, 01 Jun 2017 15:43:34 +0000
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Baxter International, Inc. with the following peers – Cardinal Health, Inc., Boston Scientific Corporation, Stryker Corporation, Zimmer Biomet Holdings, Inc., Becton, Dickinson and Company, Halozyme Therapeutics, Inc., C. R. Bard, Inc., Thermo Fisher Scientific Inc., Fresenius Medical Care AG & Co. KGaA Sponsored ADR and … Read more
Also on Market Tamer…
Follow Us on Facebook